Integrum presents health economic study of the OPRA[TM] Implant System showing long-term benefits for transfemoral amputees in the U.S.
Mölndal, Sweden, November 17, 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the initial cost-effectiveness analysis of the OPRATM Implant System focused on US healthcare data was presented at the 99th Annual ACRM Annual Conference in Chicago. The study concluded that for active transfemoral amputees, the use of the OPRATM Implant System is a cost-effective alternative to a socket prosthesis.
The “Cost-effectiveness analysis of osseointegrated prostheses for transfemoral amputation” poster was presented by Jeff Voigt, MBA, MPH, the lead author, at the 99th Annual ACRM conference on November 9th, 2022. The American Congress of Rehabilitation Medicine (ACRM) is a nonprofit professional association focusing on advancing physical medicine and rehabilitation research and care and this conference is the largest interdisciplinary rehabilitation research conference in the world.
The poster summarized the first cost-effectiveness analysis for the US covering the lifetime costs and effectiveness of the OPRA™ Implant System for transfemoral use in amputees versus a socket prosthesis. Markov health state transition models as well as probabilistic sensitivity analyses were used to perform the cost-effectiveness analyses in various health states that a patient may be in over a typical 42-year life span, wearing a socket prosthesis or having an OPRA™ Implant System.
This initial study concluded that for active transfemoral amputees, the use of the OPRA™ Implant System is a cost-effective alternative to a socket prosthesis when evaluated with a disease-specific health instrument “The Questionnaire for Persons with a Transfemoral Amputation” (Q-TFA). The values of $228/QALY (Quality Adjusted Life Years) for treatment refractory (i.e. those patients who had problems with a socket prosthesis and then switched to an OPRA™ prosthesis) and $84/QALY for treatment naïve (i.e. those patients who have not had a socket prosthesis) are well within accepted threshold values of US cost-effectiveness therapies (<$50,000/QALY). The quality-adjusted life year (QALY) is the academic standard for measuring how well all different kinds of medical treatments lengthen and/or improve patients' lives, and therefore the metric has served as a fundamental component of cost-effectiveness analyses in the US and around the world for more than 30 years.
“We are pleased to build upon this definitive evidence that the OPRA™ Implant System should be considered a reasonable alternative for socket prosthesis patients who are physically active transfemoral amputees. We look forward to sharing these findings with our customers and payers,” said Tom Dugan, president of Integrum US.
A more comprehensive manuscript on this study is in development with co-authors from multiple clinical specialties that work with patients who undergo osseointegration procedures.
